AR015926A1 - Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades - Google Patents
Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedadesInfo
- Publication number
- AR015926A1 AR015926A1 ARP980103512A ARP980103512A AR015926A1 AR 015926 A1 AR015926 A1 AR 015926A1 AR P980103512 A ARP980103512 A AR P980103512A AR P980103512 A ARP980103512 A AR P980103512A AR 015926 A1 AR015926 A1 AR 015926A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- diseases
- cells obtained
- oncogene
- stages
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108700020796 Oncogene Proteins 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000006508 oncogene activation Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Células para su aplicacion en la terapia génica que son obtenibles por: a) aislamiento de células a partir de la sangre o de los líquidos corporales quecontienen células; b) cultivacion de las células obtenidas en la etapa a) en un medio de cultivoq ue contiene gangliosidos, fosfolípidos, glicolípidos y/ofactores de crecimiento; c) facultativamente, inmortalizacion de las células obtenidas en las etapas a) o b) por trasnformacion con un oncogén, activacion deun oncogén o inactivacion de ungen s upresor; d) transfeccion de las células obtenidas en las etapas a) y b) o en la etapa c) con una estructura artificial deácido nucleico para la terapia génica, que contiene un gen efector, el cual puede ser activado por apropiados sistemas depromoto res de modo específico paracélulas diana, de modo específico para ciclos celulares, de modo específico para virus y/o por hipoxia; y la utilizacion de estas células para la preparacionde un medicamento destinado al tratamiento de unaenfermedad que s e selecciona entre el grupo que consta de tumores, leucemias, enfermedades autoinmunes,alergias, artritis, inflamaciones, rechazos de organos, reacciones de trasplante frente a hospedante, enfermedades de coagulacion de la sangre,enfermedades dela c irculacion, anemia, infecciones, enfermedades hormonales y lesiones de sistema nervioso central.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19731154A DE19731154C2 (de) | 1997-07-21 | 1997-07-21 | Genetisch veränderte Endothelzellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
| DE19752299 | 1997-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015926A1 true AR015926A1 (es) | 2001-05-30 |
Family
ID=26038441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980103512A AR015926A1 (es) | 1997-07-21 | 1998-07-17 | Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20020098166A1 (es) |
| EP (1) | EP0893493A3 (es) |
| JP (1) | JPH1189587A (es) |
| KR (1) | KR19990014018A (es) |
| AR (1) | AR015926A1 (es) |
| AU (1) | AU757960B2 (es) |
| BR (1) | BR9802542A (es) |
| CA (1) | CA2237698A1 (es) |
| CZ (1) | CZ227198A3 (es) |
| HU (1) | HUP9801634A3 (es) |
| ID (1) | ID20600A (es) |
| PL (1) | PL327624A1 (es) |
| RU (1) | RU2205029C2 (es) |
| TR (1) | TR199801395A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787464B1 (fr) * | 1998-12-21 | 2003-01-10 | Neurotech | Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers |
| ATE275629T1 (de) | 1999-04-02 | 2004-09-15 | Hisamitsu Pharmaceutical Co | Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie |
| BR9917500A (pt) * | 1999-09-23 | 2002-05-21 | An Go Gen Inc | Terapia gênica baseada em célula para o sistema pulmonar |
| US20030049635A1 (en) * | 2000-11-08 | 2003-03-13 | City Of Hope | Measurement of mutation load using the p53 gene in human cells from paraffin embedded tissues |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US7101977B2 (en) | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| US7943378B2 (en) | 2002-03-15 | 2011-05-17 | Duke University | Tissue engineering |
| EP1490477A4 (en) * | 2002-04-02 | 2006-08-30 | Univ Rice William M | REDIFFERENCED CELLS USED TO REPAIR CARTILAGE DEFECTS |
| DK1458853T3 (da) * | 2002-05-16 | 2010-04-06 | Absorber Ab | Fremgangsmåde til donorspecifik krydsmatchning |
| WO2005010157A2 (en) * | 2003-07-15 | 2005-02-03 | Cedars-Sinai Medical Center | Use of pleiotrophin in the diagnosis, treatment and prevention of disease |
| KR100676922B1 (ko) * | 2005-06-29 | 2007-02-05 | 정하철 | 혈 표시용 반지 |
| JP2009511081A (ja) * | 2005-10-18 | 2009-03-19 | ナショナル ジューイッシュ メディカル アンド リサーチ センター | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
| RU2299073C1 (ru) * | 2005-11-11 | 2007-05-20 | ЗАО "РеМеТэкс" | Биотрансплантат и способ лечения хронической сердечной недостаточности (варианты) |
| RU2308280C1 (ru) * | 2006-03-21 | 2007-10-20 | ГУ Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) | Способ клонирования in vitro регионарных клеток-предшественников сердца |
| RU2499599C2 (ru) * | 2007-09-28 | 2013-11-27 | Интрексон Корпорейшн | Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение |
| KR101803099B1 (ko) * | 2008-05-16 | 2017-11-30 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| US9169462B2 (en) * | 2008-07-21 | 2015-10-27 | Taiga Biotechnologies, Inc. | Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells |
| JP5812861B2 (ja) | 2008-08-28 | 2015-11-17 | タイガ バイオテクノロジーズ，インク． | Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法 |
| BRPI0921371A2 (pt) * | 2008-11-25 | 2014-11-18 | Otsuka Pharmaceutica Co Ltd | Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas. |
| WO2013186793A1 (en) | 2012-06-11 | 2013-12-19 | Council Of Scientific & Industrial Research | Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells |
| CA2879667C (en) | 2012-07-20 | 2021-11-16 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| CN108138142A (zh) | 2015-09-24 | 2018-06-08 | 塞莱克特生物疗法有限公司 | 繁殖用在移植中的间质干细胞（msc）的方法 |
| WO2018102678A1 (en) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| EP3952909A4 (en) | 2019-04-08 | 2023-06-07 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS |
| CA3137031A1 (en) | 2019-05-14 | 2020-11-19 | Yosef Refaeli | Compositions and methods for treating t cell exhaustion |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509467A (ja) * | 1991-04-04 | 1994-10-27 | アメリカ合衆国 | 内皮細胞の不死化 |
| FR2681609B1 (fr) * | 1991-09-24 | 1994-12-30 | Centre Nat Rech Scient | Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale. |
| WO1993013807A1 (en) * | 1992-01-10 | 1993-07-22 | Georgetown University | A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy |
-
1998
- 1998-07-15 EP EP98113137A patent/EP0893493A3/de not_active Withdrawn
- 1998-07-17 AR ARP980103512A patent/AR015926A1/es unknown
- 1998-07-17 ID IDP981018A patent/ID20600A/id unknown
- 1998-07-20 AU AU77466/98A patent/AU757960B2/en not_active Ceased
- 1998-07-20 CZ CZ982271A patent/CZ227198A3/cs unknown
- 1998-07-20 RU RU98113791/14A patent/RU2205029C2/ru not_active IP Right Cessation
- 1998-07-20 TR TR1998/01395A patent/TR199801395A2/xx unknown
- 1998-07-20 HU HU9801634A patent/HUP9801634A3/hu unknown
- 1998-07-20 CA CA002237698A patent/CA2237698A1/en not_active Abandoned
- 1998-07-21 BR BR9802542-2A patent/BR9802542A/pt not_active IP Right Cessation
- 1998-07-21 KR KR1019980029235A patent/KR19990014018A/ko not_active Withdrawn
- 1998-07-21 JP JP10205261A patent/JPH1189587A/ja active Pending
- 1998-07-21 US US09/119,659 patent/US20020098166A1/en not_active Abandoned
- 1998-07-21 PL PL98327624A patent/PL327624A1/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9801634A3 (en) | 2003-07-28 |
| HUP9801634A2 (hu) | 1999-06-28 |
| HU9801634D0 (en) | 1998-09-28 |
| AU757960B2 (en) | 2003-03-13 |
| BR9802542A (pt) | 2000-01-11 |
| KR19990014018A (ko) | 1999-02-25 |
| EP0893493A3 (de) | 2002-12-04 |
| AU7746698A (en) | 1999-02-04 |
| US20020098166A1 (en) | 2002-07-25 |
| EP0893493A2 (de) | 1999-01-27 |
| JPH1189587A (ja) | 1999-04-06 |
| CZ227198A3 (cs) | 1999-02-17 |
| PL327624A1 (en) | 1999-02-01 |
| RU2205029C2 (ru) | 2003-05-27 |
| CA2237698A1 (en) | 1999-01-21 |
| ID20600A (id) | 1999-01-21 |
| TR199801395A2 (xx) | 1999-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015926A1 (es) | Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades | |
| JP2022000036A (ja) | 改変された細胞および治療の方法 | |
| Pan et al. | SCF promotes dental pulp progenitor migration, neovascularization, and collagen remodeling–potential applications as a homing factor in dental pulp regeneration | |
| CN107893076A (zh) | CRISPR‑Cas9靶向敲除人乳腺癌细胞RASSF2基因及其特异性的sgRNA | |
| CN109294985A (zh) | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 | |
| RU2017121191A (ru) | Методика размножения гамма-дельта Т-клеток | |
| ES2773155T3 (es) | Método para tratar leucemia usando un efecto reprogramante | |
| BRPI0411856A (pt) | composições e métodos para o aumento da atividade de telomerase | |
| JP2017537625A5 (es) | ||
| GB2617799A (en) | Gene silencing | |
| US20190194622A1 (en) | Generation of cancer stem cells and use thereof | |
| BR0211491A (pt) | Geração de células dendrìticas totalmente madura e estáveis de produtos de leucafereses para aplicações clìnicas | |
| Yin et al. | A battery-free nanofluidic intracellular delivery patch for internal organs | |
| JP2025038215A (ja) | Ｍｒｎａの増幅のための方法及び組成物 | |
| CN111903603A (zh) | 用于构建胆管癌异种移植模型的移植体及其制备方法和用途 | |
| Dong et al. | A nano-immunotraining strategy to enhance the tumor targeting of neutrophils via in vivo pathogen-mimicking stimulation | |
| TW200413014A (en) | Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation | |
| CN105087477A (zh) | miR-21反义核苷酸修饰的骨髓间充质干细胞的用途 | |
| RU2728592C1 (ru) | Способ стимуляции презентирующей активности дендритных клеток | |
| Kato et al. | RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6. 3 prostate cancer | |
| Bekesi et al. | Impact of specific immunotherapy in acute myelocytic leukemia | |
| Sidik | How to trick the immune system into attacking tumours | |
| JPH01221327A (ja) | 形質転換又は腫瘍細胞を選択的に死滅させるための剤として使用されるセット又はキット | |
| CN114606195A (zh) | 一种低强度脉冲超声增强胶质瘤干细胞对替莫唑胺敏感性的方法 | |
| CN113930423B (zh) | 保护心肌细胞免受应激损伤的saRNA及其应用 |